个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Impact of neoadjuvant chemotherapy on the postoperative pathology of locally advanced cervical squamous cell carcinomas: 1:1 propensity score matching analysis.

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Li Pengfei[1] * ; Fang Ziyu[1] * ; Li Weili[1] * ; Hao Min[2] ; Wang Wuliang[3] ; Kang Shan[4] ; Guo Jianxin[5] ; Yang Ying[6] ; Ni Yan[7] ; Zhao Weidong[8] ; Lu Anwei[9] ; Ling Bin[10] ; Li Donglin[11] ; Lang Jinghe[12] ; Chen Chunlin[1,*1] ; Liu Ping[1,*1] ;
机构： [1]Department of Obstetrics and Gynecology, Nan Fang Hospital, Southern Medical University, Guangzhou, Guangdong, China [2]Department of Obstetrics and Gynecology, Second Hospital of Shanxi Medical University, Taiyuan, Shangxi, China [3]Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zhengzhou University, Henan, China [4]Department of Gynecology, Fourth Hospital, Hebei Medical University, Shijiazhuang, China [5]Department of Obstetrics and Gynecology, Daping Hospital, Army Medical University, Chonqing, China [6]Department of Obstetrics and Gynecology, Xinqiao Hospital, Army Medical University, Chongqing, China [7]Department of Obstetrics and Gynecology, Yuncheng Central Hospital, Yuncheng, China [8]Department of Gynaecology, Anhui Cancer Hospital, HeFei, China [9]Department of Gynecology, The Maternity and Child Care Hospital of Guizhou Province, Guiyang, China [10]Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing, China [11]Department of Obstetrics and Gynecology, Guizhou Provincial People’s Hospital, Guiyang, China [12]Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China
出处：
DOI： 10.1016/j.ejso.2020.09.013
ISSN：

关键词： Neoadjuvant chemotherapy Locally advanced Cervical squamous cell carcinomas Postoperative pathology

摘要：
To assess the impact of neoadjuvant chemotherapy on postoperative pathology for stage IB2 and IIA2 cervical squamous cell carcinoma. Postoperative pathology was compared between patients who received neoadjuvant chemotherapy followed by radical hysterectomy (NACT group) and patients who received upfront radical hysterectomy (URH group). Then, patients in the NACT group were divided into a chemotherapy-sensitive group and a chemotherapy-insensitive group according to their response to chemotherapy. After 1:1 propensity score matching (PSM), the positive rates of lymphovascular space invasion (LVSI) (7.9% vs 17.7%, P = 0.001) and cervical deep stromal invasion (60.4% vs 76.2%, P < 0.001) in the NACT group were significantly lower than those in the URH group, while the positive rates of parametrial invasion, lymph node metastasis, and vaginal margin invasion were not significantly different between the two groups. The rate of positive lymph node metastasis in the chemotherapy-sensitive group was significantly lower than that in the URH group (18.1% vs 26.5%, P = 0.037). Among patients with stage IB2 and IIA2 cervical squamous cell carcinomas, NACT can reduce the positive rate of intermediate-risk factors, such as deep cervical stromal invasion and LVSI, but cannot reduce the positive rate of high-risk factors. For patients who are chemotherapy sensitive, NACT can reduce the positive rate of lymph node metastasis. Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

基金：
National Science and Technology Support Program of China (2014BAI05B03), the National Natural Science Fund of Guangdong (2015A030311024), the Science and Technology Plan of Guangzhou (158100075).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2021]版：
大类 | 3 区 医学
小类 | 2 区 外科 3 区 肿瘤学
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学 2 区 外科
JCR分区：
出版当年[2021]版：
Q1 SURGERY Q3 ONCOLOGY
最新[2024]版：
Q1 SURGERY Q2 ONCOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Department of Obstetrics and Gynecology, Nan Fang Hospital, Southern Medical University, Guangzhou, Guangdong, China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Obstetrics and Gynecology, Nan Fang Hospital, Southern Medical University, Guangzhou, Guangdong, China [*1]Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, No. 1838, Guangzhou Avenue, Guangzhou, 510515, China
推荐引用方式(GB/T 7714)：
Li Pengfei,Fang Ziyu,Li Weili,et al.Impact of neoadjuvant chemotherapy on the postoperative pathology of locally advanced cervical squamous cell carcinomas: 1:1 propensity score matching analysis.[J].EJSO.2021,47(5):1069-1074.doi:10.1016/j.ejso.2020.09.013.
APA：
Li Pengfei,Fang Ziyu,Li Weili,Hao Min,Wang Wuliang...&Liu Ping.(2021).Impact of neoadjuvant chemotherapy on the postoperative pathology of locally advanced cervical squamous cell carcinomas: 1:1 propensity score matching analysis..EJSO,47,(5)
MLA：
Li Pengfei,et al."Impact of neoadjuvant chemotherapy on the postoperative pathology of locally advanced cervical squamous cell carcinomas: 1:1 propensity score matching analysis.".EJSO 47..5(2021):1069-1074

相关文献

[1]Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma [2]Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma [3]Current neoadjuvant therapy for operable locally advanced esophageal cancer [4]Deep learning nomogram for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer patients [5]Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis. [6]Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma. [7]The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma [8]The efficacy and safety of neoadjuvant sintilimab combined with chemotherapy in elderly patients with locally advanced esophageal squamous cell carcinoma [9]Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial : A randomized clinical trial of neoadjuvant therapy for ESCC [10]F-18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Metabolic Parameters Before and After Neoadjuvant Chemotherapy Can Predict the Postoperative Prognosis of Locally Advanced Gastric Cancer

资源点击量：42329 今日访问量：0 总访问量：1365 更新日期：2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号